Angiotensin Receptor Blockers (ARBs) vs CancerA study says that drugs known as Angiotensin Receptor Blockers (ARBs) can cause a modestly increased risk of the cancer.
Angiotensin receptor blockers (ARBs) are drugs commonly used to lowering high blood pressure, reduce heart failure and diabetic nephropathy.
The researchers found patients were randomized to receive an ARB has a 7.2% risk of developing a new cancer, compared to 6% in the control group in the study. Among solid-organ cancers examined, only the incidence of new lung cancer was significantly higher in recipients of ARB from the control group, 0.9% compared to 0.7%.
In a written statement, Boehringer Ingelheim said the comprehensive security of internal data analysis of primary data contrary to the Lancet study conclusions about potential increased risk of malignancy. The company says the drug has been studied in clinical trials in more than 50 000 patients, and has a positive safety profile.
A combined sale of Novartis’s Diovan and related drugs, Co-Diovan, last year was $ 6 billion. Merck’s Cozaar and Hyzaar drug-related have combined sales of $ 3.6 billion.
No comments:
Post a Comment